Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss.

Abstract

Recent evidence from clinical trials supports the efficacy and tolerability of glucagon-like peptide 1 (GLP-1) receptor agonists as useful agents for weight loss. Although originally developed as glucose lowering agents for people with type 2 diabetes, progress in research over the last 3 decades has demonstrated that GLP-1 receptor agonists act in the central nervous system to reduce food intake. This minireview summarizes key aspects of GLP-1 biology and the clinical studies supporting the utility of the GLP-1 receptor signaling system as a therapeutic target for weight loss.

• Authors: Nitya Kumar, David A D'Alessio
• Journal: The Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 107 Issue 8 Pg. 2148-2153 (07 14 2022) ISSN: 1945-7197 [Electronic] United States
• PMID: 35536590 (Publication Type: Journal Article, Review)
• Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: [email protected].

Chemical References

• Glucagon-Like Peptide-1 Receptor
• Hypoglycemic Agents
• Glucagon-Like Peptide 1

Topics

• Diabetes Mellitus, Type 2 (drug therapy)
• Glucagon-Like Peptide 1 (therapeutic use)
• Glucagon-Like Peptide-1 Receptor (agonists)
• Humans
• Hypoglycemic Agents (pharmacology, therapeutic use)
• Weight Loss